by Raynovich Rod | Feb 20, 2024 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-1 2/23/24. You know the story by now it’s all about AI and NVDA. As my friend said in the mid -90s “there is no end to chips Rod”. Overall one of the best weeks for the market but of course led by technology stocks. The equal weight small cap...
by Raynovich Rod | Jun 23, 2020 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3…June 25-Re-opening Paused in FLA and TX-but stocks rally anyway. NASDAQ leads up 11% YTD. Trading remains volatile e.g. VIR. Bullish trend intact for biotech IBB up 1.11%. Vaccine stocks continue strong: BNTX INO NVAX ; MRNA lagging. Diagnostic leaders...
by Raynovich Rod | Aug 6, 2019 | Clinical Diagnostics and Tools
8/10/19…XBI up 1.8% to $84.04 for 5 days, QQQ up 1.9% to $185.81 over 5 days.A good week for life science stocks with following stocks near 52 week highs: BDX BIO DHR GH HOLX NVTA 8/8/19 9:45a EDT Life Science Movers…Stocks to Watch…XBI up 0.61% to...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Aug 7, 2017 | 2020-21 Life Science Portfolios, Clinical Diagnostics and Tools
8/10 Red Screen in the Morning We cautioned on XBI at $78 on 7/31 and today it broke through support at $75 to $74.70. ======= 8/9 Update After Close: A Bit of Caution after Trump’s “Fire and Fury” Talk Investors are holding off as global risks rise...
by Raynovich Rod | Sep 6, 2016 | Clinical Diagnostics and Tools
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of...
by Raynovich Rod | Jan 13, 2016 | 2020-21 Life Science Portfolios, Clinical Diagnostics and Tools
Green Screen Alert Market Update…IBB up 4% today erasing most of Wednesday’s Losses but we are still down 13.86% for the five day period. Nasdaq rallied 1.97%. Rayno Biopharma top winners: ABBV up 6.56%, ALXN up 5.93%, AMGN up 5.29%,BIIB up 4.98%, REGN up...
by Raynovich Rod | Nov 5, 2015 | 2023 Rayno Tools and Diagnostics Portfolio
Looking for Value in a Slow Growth Market Life Science stocks took a big hit over the past summer and many have not fully recovered.The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE...
by Raynovich Rod | Sep 16, 2015 | 2023 Rayno Tools and Diagnostics Portfolio
10/7/15 Update…Still in No Man’s Land…Nothing to Do See recent posts on bear market in biotech. We need to wait for Q3 earnings to find trades and longer term value in Dx and Tools. Most stocks in the sector have been hit hard since August....
by Raynovich Rod | Jun 12, 2015 | BIOgraph
We will be attending the BIO International Convention in Philadelphia next week. Sign up now to receive life science industry news.